Noojerone, pills 10mg 90pcs

Composition

of 1 tab. Memantine hydrochloride 10 mg

Auxiliary substances:

microcrystalline cellulose,

calcium hydrophosphate,

croscarmellose sodium,

colloidal silicon dioxide,

magnesium stearate.

Composition of the film shell:

opadray II grey 45F27505 (hypromellose 2910/15 cP, polydextrose, titanium dioxide, macrogol/macrogol-4000, iron oxide dye black) 

Pharmacological action

is psychometabolic, nootropic.

Indications

-moderate to severe dementia in Alzheimer’s disease.

Contraindications

hypersensitivity to any of the components of the drug; severe hepatic insufficiency; pregnancy; breastfeeding; age up to 18 years (the effectiveness and safety of the drug have not been studied).

With caution: epilepsy; renal failure; thyrotoxicosis; convulsions in the anamnesis; arterial hypertension; myocardial infarction in the anamnesis; heart failure.

Side effects

From the nervous system: dizziness, headache, drowsiness, gait disorders, confusion, hallucinations, convulsions, psychosis, increased excitability.

Gastrointestinal disorders: constipation, vomiting, pancreatitis, nausea. Infections and infestations: fungal infections.

From the cardiovascular system: increased blood pressure, venous thrombosis, thromboembolism.

From the body as a whole: general weakness, increased fatigue, allergic reactions.

Interaction

When administered concomitantly, it may weaken the effect of barbiturates and neuroleptics.

The effect of baclofen and dantrolene may change under the influence of memantine, so it may be necessary to adjust their doses. The effects of levodopa, dopamine receptor agonists, and anticholinergics are enhanced by concomitant use of NMDA antagonists.

Due to the fact that memantine and amantadine are antagonists of NMDA receptors, simultaneous use should be avoided due to the risk of toxic effects.

Combinations of memantine with ketamine, dextromethorphan, and phenytoin are also potentially toxic.

For the transport of amantadine, cimetidine, ranitidine, quinidine, quinine and nicotine in the body, the same renal cationic system is used, which may cause the interaction of these drugs with memantine, leading to an increase in its concentration in blood plasma.

How to take, course of use and dosage

Inside, regardless of food intake.

During the first week, the daily dose is 5 mg (in the morning).

In the second week, the daily dose is 10 mg (5 mg 2 times a day). During the third week, the daily dose is 15 mg (10 mg in the morning and 5 mg in the evening).

From the fourth week, the daily dose is 20 mg. The maximum daily dose is 20 mg.

Special patient groups

Elderly patients.

Dose adjustment in elderly patients (over 65 years of age) not required.

Impaired renal function.

In moderate renal insufficiency (creatinine clearance 50-80 ml/min), dose adjustment is usually not required; in creatinine clearance 30-49 ml/min, the daily dose initially does not exceed 10 mg, then after 7 days, if well tolerated, the dose can be increased up to 20 mg.

In severe renal insufficiency (creatinine clearance 5-29 ml / min), the daily dose should not exceed 10 mg.

Impaired liver function.

No dose adjustment is required for mild to moderate hepatic insufficiency (Child-Pugh class A and B).

Overdose

Symptoms: dizziness, tremor, agitation, drowsiness, confusion, agitation, stupor, convulsions, aggressiveness, hallucinations, unsteadiness of gait, vomiting, diarrhea.

Treatment: gastric lavage, use of activated charcoal; symptomatic therapy. There is no specific antidote.

Storage conditions

 In a dark place, at a temperature not exceeding 25 °C.

Shelf life

2 years

Active ingredient

Memantine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Acquired Dementia, Alzheimer ‘s Disease